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Abstract
Pandoraea sp. is an emerging Gram-negative pathogen in cystic fibrosis causing severe and persistent inflammation and damage
of the lungs. The molecular mechanisms underlying the high pathogenicity of Pandoraea species are still largely unknown. As
Gram-negatives, Pandoraea sp. express lipopolysaccharides (LPS) whose recognition by the host immune system triggers an
inflammatory response aimed at the bacterial eradication from the infected tissues. The degree of the inflammatory response
strongly relies on the fine structure of the LPS and, in particular, of its glycolipid moiety, i.e. the lipid A. Here we report the
structure of the lipid A isolated from the LPS of a chronic strain of P. pulmonicola (RL 8228), one of the most virulent identified
so far among the Pandoraea species. Our data demonstrated that the examined chronic strain produces a smooth-type LPS with a
complex mixture of hypoacylated lipid A species displaying, among other uncommon characteristics, the 2-hydroxylation of
some of the acyl chains and the substitution by an additional glucosamine on one or both the phosphate groups.
Keywords Lipopolysaccharide . Cystic Fibrosis . Pandoraea . Lipid A . Structural characterization . MALDI-TOF Mass
spectrometry

Introduction
Cystic fibrosis (CF) is an incurable, chronic disease, caused by
defects in genes encoding for the CF transmembrane conductance regulator (CFTR), a chloride channel which regulates
the activity of other chloride and sodium channels at the cell
surface epithelium [1]. Defective CFTR results in abnormal
movement of salts and water across the cells which leads to
dehydration of the airway surfaces and production of a thick
and sticky mucus obstructing the pathways. This clog of the
airways leads to breathing problems and to repeated and
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serious lung infections with damaging inflammation [2].
Indeed, the main cause of morbidity and mortality for CF
patients is associated to infection by bacterial pathogens and
opportunistic pathogens encountered throughout their lives.
Beside Pseudomonas aeruginosa and bacteria of the
Burkholderia cepacia complex, which are well-known
Gram-negative opportunistic pathogens able to persistently
colonize CF respiratory tract, Pandoraea species are considered as emerging pathogens leading to worsened CF lung
disease [3].
Several species of Pandoraea have been identified so far,
with P. pulmonicola representing the predominant species
isolated in Irish CF patients. Moreover, P. pulmonicola is also
considered as the most invasive and virulent among the
Pandoraea species, exhibiting the capability to invade human
lung epithelial cells, a peculiarity not shared by other
Pandoraea species [4, 5]. However, still very little is known
about the molecular mechanisms of pathogenicity and virulence of Pandoraea species as well as of their intrinsic multidrug resistance [6].
A plethora of potential virulence factors have been previously defined for CF pathogens and connected with bacterial pathogenicity in CF. One of the most studied is the
lipopolysaccharide (LPS) molecule which is the main
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component of the external leaflet of the Gram-negatives
outer membrane. LPSs are crucial actors in a plethora of
host-microbe interaction events such as, among others, colonization, adhesion, and virulence [7]. Importantly, the degree of pathogenicity of LPS molecules is strictly related to
their ability to trigger the activation of the host innate and
adaptive immune responses. Indeed, the LPS is recognized
as a Pathogen-Associated Molecular Pattern (PAMP), i.e. a
molecular signature relatively conserved among Gram-negatives, by specific Pattern Recognition Receptors (PRRs) of
the host immune system. The receptorial complex made up
of Toll-like receptor-4 (TLR4) and myeloid differentiation
factor-2 (MD-2), present on the surface of several immune
phagocytic cells, is one of the most studied PRRs which
specifically recognizes the glycolipid moiety of an LPS
[7]. Upon recognition by TLR4/MD-2, an intracellular signaling cascade is activated which culminates in the production of pro-inflammatory cytokines aimed at the clearance
of the invading bacteria. However, this production of proinflammatory cytokines in immunocompromised individuals, as in the case of CF patients, is incredibly detrimental
and leads to pathological consequences associated with
high mortality [4, 5, 8].
The capability of an LPS to elicit such an inflammatory
response is strictly related to its fine structure. In general,
LPS is composed of three distinct domains: an outermost
and highly variable polysaccharidic moiety (the O-chain)
connected to an oligosaccharide (core OS) region which
is, in turn, covalently linked to a glycolipid domain (the
lipid A) which represents the anchor of the whole molecule
to the outer membrane. The lipid A is the moiety specifically recognized by the TLR4/MD-2 complex and, depending
on its structure, it can finely tune the degree of inflammatory
cytokines release [9]. In general, a lipid A is made up of a
β-(1→6) disaccharide of glucosamine (GlcN), typically
phosphorylated at position 1 and 4’, and acylated by 3hydroxy fatty acids in position 2, 2’, 3 and 3’ of the
GlcNs. These acyl chains are, in turn, commonly acylated
by other non-hydroxy fatty acids. Chemical modifications
of such a general lipid A architecture greatly impact on the
TLR4-mediated immunopotential of the whole LPS molecule. It is known that hexa-acylated lipid A with a 4 + 2
symmetry of the acyl chains with respect of the
diglucosamine backbone, exhibits the strongest TLR4mediated immune response, while tetra- and pentaacylated species have a weaker immunostimulatory capacity [7, 9]. Moreover, phosphate groups and additional decorations occurring on the glucosamine disaccharide backbone have a crucial role in the immunopotency of an LPS. In
this context, several studies have been devoted to the characterization of the structure of lipid A from CF pathogens
and opportunistic pathogens disclosing structural details involved in the bacterial pathogenicity and resistance to

antibiotic treatment [10–13]. Moreover, as in the case of
bacteria able to chronically colonize CF lungs, several lipid
A structural modifications have been observed during the
infection chronicization which can lower lipid A’s
immunoelicitation power allowing enhanced persistence in
the infected tissue [13].
Given these premises, the structural characterization of
the lipid A moiety of an LPS remains a first but essential
step in order to appreciate the molecular mechanisms underlying the LPS-mediated infection and inflammatory process
observed in CF patients. Herein, we report about the structural elucidation of the lipid A from the LPS of
P. pulmonicola strain RL8228, isolated from a chronically
colonized CF Irish patient who died 52 months after their
first Pandoraea isolation [5]. The structure has been defined
by merging information that were attained from the compositional analysis executed on pure LPS and isolated lipid A
with data from a matrix-assisted laser desorption ionization
(MALDI) time of flight (TOF) mass spectrometry (MS) and
MS2 investigation executed on the lipid A fraction and on
the bacterial pellet.

Methods
LPS extraction and purification
The bacterial pellet was kindly provided by LMG collection
of Ghent University. The LPS was extracted directly from
dried pellet by the hot phenol-water procedure [14]. The
LPS was then enzymatically digested, to remove possible cell
contaminants, using DNase (DN25-Sigma Aldrich®, St.
Louis, MO, USA), RNase (R5503-Sigma Aldrich®), and protease (P4630-Sigma Aldrich®). The digested material was
extensively dialyzed (Spectra/Por®, cut-off 12–14 kDa)
against distilled water and then ultracentrifuged (Beckman
Coulter’s ultracentrifuge, Brea, CA, USA) (200,000 × g,
4 °C, 16 h). An additional step of purification foreseen a gelfiltration chromatography on a Sephacryl High Resolution
S-400 (GE-Healthcare, Little Chalfont, UK) column. An
SDS-PAGE followed by silver nitrate gel staining (Sigma
Aldrich®, St. Louis, MO, USA) [15] was executed to ascertain the nature and the degree of purity of the extracted
material.

Compositional analyses of the fatty acid content
The total fatty acid content was determined by treating each
LPS with 4 M HCl (100 °C, 4 h), followed by a treatment
with 5 M NaOH (100 °C, 30 min). After the adjustment of
the pH, fatty acids were extracted in CHCl3 and then methylated with diazomethane and analyzed by Gas
Chromatography Mass Spectrometry (GC-MS) (Santa
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Clara, CA, USA). The ester-bound fatty acids, analyzed by
GC-MS, were recovered after treatment with aqueous 0.5 M
NaOH in CH3OH (1:1, v/v, 85 °C, 2 h), followed by acidification of the products, extraction in CHCl3 and methylation with diazomethane.
In parallel, an aliquot of each LPS fraction was also
methanolized with 1.25 M HCl/CH3OH (80 °C, 16 h). The
mixture was extracted three times with hexane. The hexane
layer, containing the fatty acids as methyl esters derivatives,
was then analyzed by GC-MS.
The absolute configuration of the fatty acids was defined as
previously reported in literature [16]. Briefly, the 3-hydroxy
fatty acids were released after treatment with 4 M NaOH
(100 °C, 5 h), converted into the 3-methoxy acid Lphenylethylamides, and then analyzed by GC-MS. The comparison of the retention times of authentic Lphenylethylamides of various standard fatty acids with those
from the P. pulmonicola LPS led the assignment of the (R)
configuration to 14:0 (3-OH) acyl moieties and the (S) configuration to 14:0 (2-OH) and 12:0 (2-OH). The analyses were
all performed on an Agilent Technologies gas chromatograph
6850A equipped with a mass selective detector 5973N and a
Zebron ZB-5 capillary column (Phenomenex, 30 m ×
0.25 mm internal diameter, flow rate 1 mL min−1, He as
carrier gas). The following temperature program was
employed for the lipid analysis: 140 °C for 3 min, 140 °C
→ 280 °C at 10 °C min− 1.

Isolation, chemical analysis, and partial de-lipidation
of the lipid A fraction
An aliquot of purified LPS was treated with acetate buffer (pH
4.4, 2 h, 100 °C) in presence of SDS, in order to selectively
cleave the lipid A from the saccharide part of the LPS. A
mixture of CHCl3 and CH3OH was added to the hydrolysis
product to obtain a CHCl3/CH3OH/hydrolysate 2:2:1.8 (v/v/v)
ratio. The mixture was then shaken and centrifuged. The chloroform phase, containing the lipid A, was collected and
washed with the water phase of a freshly prepared Bligh/
Dyer mixture (CHCl3/CH3OH/water, 2:2:1.8) [17]. The organic phases, containing the lipid A fraction, were pooled
and dried. The sample preparation methods reported here fulfill the Minimum Information Required for a Glycomics
Experiment (MIRAGE) guidelines [18].
In order to establish the nature of the sugar(s) composing
the backbone of the lipid A, an aliquot of the lipid A fraction
also underwent a methanolysis (1.25 M HCl/CH3OH, 80 °C,
16 h) followed by acetylation (80 °C, 20 min) and GC-MS
analysis [19, 20].
To partially remove the acyl chains, an aliquot of lipid A
fraction (0.3 mg) was treated with ammonium hydroxide
(NH4OH) as previously reported [21]. The sample was then

dried and analyzed by MALDI-TOF MS along with the untreated lipid A fraction.

Dephosphorylation of lipid A and derivatization to
alditol acetates
In order to unequivocally establish the nature of the additional
hexosamine(s) decorating the lipid A, around 0.6 mg of the
mild acid hydrolysis product, i.e. the isolated lipid A fraction,
was treated with 100 µL of 48% aqueous hydrofluoric acid
(HF) (Sigma Aldrich®, St. Louis, MO, USA) at 4° C for 16 h
to remove the phosphate groups. The sample was placed in an
ice bath and the HF was then evaporated util dry. The HFtreated sample was then dissolved in distilled water and lyophilized. A mixture of CHCl3/CH3OH/H2O (2:1:2 v/v/v) was
added to the sample and the upper part was collected and
lyophilized [22]. The sample was then treated with NaBH4
(Sigma Aldrich®, St. Louis, MO, USA) and then acetylated
with equal amounts of acetic anhydride in pyridine at 85 °C
for 20 min [20]. The so-obtained acetylated alditol derivative
of the isolated hexosamine was analyzed by GC-MS and compared with opportunely prepared standards.

MALDI-TOF mass spectrometry
All the MS and the MS2 experiments were performed both
in linear and reflectron mode, negative ion polarity on an
ABSCIEX TOF/TOF 5800 Applied Biosystems (Foster
City, CA, USA) mass spectrometer equipped with an
Nd:YAG laser (λ = 349 nm), with a 3 ns pulse width and a
repetition rate of up to 1000 Hz, and also equipped with
delayed extraction technology. Lipid A fraction was dissolved in CHCl3/CH3OH (50:50, v/v). The matrix solution
was 2’,4’,6’-trihydroxyacetophenone (THAP) (91,928Sigma Aldrich®) in CH 3 OH/0.1% trifluoroacetic
acid/CH3CN (7:2:1, v/v/v) at a concentration of 75 mg/mL
[23–25]. The NH4OH-treated lipid A was instead dissolved
in CHCl3-trifluoroethanol (4:1, v/v) and the matrix used was
2,5-dihydroxy benzoic acid (DHB) (85,707-Sigma
Aldrich®) in acetonitrile 0.2% trifluoroacetic acid (7:3,
v/v) [21]. In the case of analysis of the bacterial pellet, the
matrix used was DHB at a final concentration of 10 mg/mL
in CHCl3/CH3OH (9:1, v/v) as previously reported [26]. In
all the cases, 0.5 µL of the sample and 0.5 µL of the matrix
solution were deposited onto a stainless-steel plate and left
to dry at room temperature. Each spectrum in the MS experiments was a result of the accumulation of 2000 laser shots
(raw file was uploaded to Glycopost (GPST000137 https://
glycopost.glycosmos.org/), whereas 5000–7000 shots were
summed for the MS2 spectra. Each experiment was performed in triplicate.
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Fig. 1 Negative-ion MALDI-TOF (reflectron mode) mass spectrum of
the lipid A from P. pulmonicola RL8228 obtained by mild acid treatment
of the purified LPS. Differences of 16 amu are reported in the spectrum.

Differences in the nature of the acyl chains have been also indicated. “P”
indicates the phosphate group; “HexN” indicates differences of 161 amu
(i.e. a hexosamine unit)

Results

extremely complex pattern of signals relative to deprotonated
[M-H]− lipid A species differing in the nature and number of
the fatty acid chains and in the phosphate content. Moreover,
the spectrum displayed additional peaks differing in 161 amu,
which likely suggested the occurrence of lipid A species characterized by hexosamine (HexN) modification on one or both
phosphate groups of the disaccharide backbone (Fig. 1;
Table 1).
Briefly, mono- and bis-phosphorylated tri- to pentaacylated lipid A species have been identified in the mass range
m/z 1082.1–1946.9, with a visibly clear high heterogeneity
due also to differences of 16 amu occurring between most of
the peaks, indicative of lipid A species differing in the absence
or presence of hydroxylated acyl chains. The main peak at m/z
1376.3 was matched with a bis-phosphorylated tetra-acylated
lipid A species carrying two primary N-linked 14:0 (3-OH),
one O-linked primary 14:0 (OH), and one secondary 12:0 (2OH), whose mono-phosphorylated form was detected at m/z
1296.4 (Fig. 1; Table 1). Moreover, the related bis-phosphorylated penta-acylated lipid A form bearing an additional hydroxylated 14:0 moiety with respect to species at m/z 1376.3,
matched with peak at m/z 1602.5 (Table 1). Interestingly,
starting from the mono-phosphorylated tetra-acylated lipid A
species at m/z 1296.4, it was possible to identify a related
species decorated by one additional HexN (differing for 161
amu) matching with peak at m/z 1457.5; the corresponding
penta-acylated form, carrying another secondary 14:0 (2OH), was identified at m/z 1683.7 (Fig. 1; Table 1).
Furthermore, the spectrum showed an additional series of
peaks which are not directly related to any other known modifications of the lipid A but predicted to belong to lipid A as
the differences between them (198 and 80 amu from m/z
1398.3 to m/z 1200.1, and to m/z 1318.4) can be attributed
to one 12:0 (OH) and one phosphate group, respectively.
Moreover, starting from the lipid A species at m/z 1398.4,
additional lipid A forms were identified as decorated by one
HexN (m/z 1559.5), one HexN and one 14:0 (OH) (m/z
1785.7), and two HexNs and one 14:0 (OH) (m/z 1946.9).
Notably, the negative-ion MALDI-TOF mass spectrum,

Isolation of the LPS and compositional analysis of the
lipid A from P. pulmonicola strain RL8228
The LPS material was isolated from lyophilized bacterial cells
and checked via SDS-PAGE after silver nitrate gel staining
[14, 15]. This analysis showed that P. pulmonicola RL8228
expresses an S-LPS as proven by the ladder-like pattern in the
upper part of the gel, indicative of the presence of the O-chain
moiety. After purification of the LPS, a detailed compositional
analysis was performed to establish the fatty acid content,
revealing the occurrence of (R)-3-hydroxytetradecanoic acid
(14:0 (3-OH)) in both ester and amide linkages, whereas (S)-2hydroxytetradecanoic (14:0 (2-OH)), (S)-2hydroxydodecanoic (12:0 (2-OH)), dodecanoic (12:0) and
tetradecanoic acid (14:0) were found only as ester-bound acyl
chains.
In order to elucidate the structure of the lipid A moiety, an
aliquot of the LPS underwent a mild acid hydrolysis, which
selectively cleaves the acid labile glycosidic linkage bridging
the core OS with the lipid A portion. Once obtained the lipid A
fraction, an aliquot underwent a compositional analysis to
define the nature of the lipid A sugar backbone. This analysis
revealed the occurrence of GlcN as the only sugar composing
the lipid A moiety.
In parallel, another aliquot of the LPS mild acid hydrolysis
product underwent a detailed MALDI-TOF MS and MS2
analysis to establish the fine structure of the lipid A. Finally,
in order to avoid any loss of structural information, a MALDITOF investigation of the lipid A was also executed directly on
the bacterial pellet, as previously described [26].

MALDI-TOF MS and MS2 analysis on the isolated lipid
A from P. pulmonicola strain RL8228
The reflectron MALDI-TOF MS spectrum, recorded in negative ion polarity, of the isolated lipid A from P. pulmonicola
RL8228 is reported in Fig. 1. The spectrum clearly showed an

Content courtesy of Springer Nature, terms of use apply. Rights reserved.

Glycoconj J
Table 1 The main ion peaks
observed in the MALDI-TOF MS
spectrum reported in Fig. 1, the
predicted mass and the proposed
interpretation of the substituting
fatty acids and phosphates on the
P. pulmonicola RL8228 lipid A
backbone

Predicted mass
(Da)

Observed ion peaks
(m/z)

Acyl
substitution

Proposed fatty acid/phosphate composition

1098.69
1178.66
1296.86
1376.82
1456.92
1523.05

1098.16
1178.16
1296.41
1376.35
1457.48
1522.62

Tri-acyl
Tri-acyl
Tetra-acyl
Tetra-acyl
Tetra-acyl
Penta-acyl

1537.89
1603.02
1684.12

1537.50
1602.59
1683.75

Tetra-acyl
Penta-acyl
Penta-acyl

HexN2P [14:0(3-OH)]3
HexN2P2 [14:0(3-OH)]3
HexN2P [14:0(3-OH)]3[12:0(2-OH)]
HexN2P2 [14:0(3-OH)]3[12:0(2-OH)]
HexN3P [14:0(3-OH)]3[12:0(2-OH)]
HexN2P [14:0(3-OH)]3[12:0(2-OH)]
[14:0(2-OH)]
HexN3P2 [14:0(3-OH)]3[12:0(2-OH)]
HexN2P2 [14:0(3-OH)]4[12:0(2-OH)]
HexN3P [14:0(3-OH)]4[12:0(2-OH)]

The observed masses reported in the table are compared to the calculated molecular weight (predicted mass, Da)
of each ion based on the proposed lipid A structures.

which was recorded directly on the intact bacterial cells (Fig.
S-1), confirmed the structural determination deduced by analysis of the isolated lipid A fraction (Fig. 1). This observation
consolidated the results and excluded any lack of structural
information possibly occurring as a consequence of the chemical treatment to isolate the lipid A.
In order to meticulously delineate the structure of
P. pulmonicola RL8228 lipid A, that is defining the exact
location of the acyl chains, phosphates and additional HexN
with respect to the diglucosamine backbone, a negative-ion
MS2 analysis was performed on various peaks. The MS2
spectrum of precursor ion at m/z 1296.4 (Fig. 2), chosen as
a representative of mono-phosphorylated tetra-acylated lipid A species, showed an intense peak at m/z 1052.4

attributed to an ion derived from the loss of one primary
14:0 (3-OH). However, an important peak, in terms of structural characterization, was identified at m/z 812.4 which was
attributed to an ion originating from the sugar ring fragmentation 0,2A2 [27] which demonstrated that (i) two hydroxylated 14:0 chains and the phosphate decorated the nonreducing glucosamine unit, and suggested (ii) that the hydroxyl group at position 3 of the reducing glucosamine was
free; this, in turn, proved that (iii) the 12:0 (2-OH) acyl chain
was present as a secondary substituent of the primary
amide-bound 14:0 (3-OH) of the reducing glucosamine. A
further sugar ring fragmentation (0,4A2) [27] at m/z 752.4
was also identified, and concurred to confirm the above
structural hypothesis.

Fig. 2 Negative-ion MALDI MS2 spectra of precursor ion at m/z 1296.4
of the lipid A isolated from. P. pulmonicola RL8228. This is a
representative ion peak of the cluster ascribed to tetra-acylated lipid A
species decorated by one phosphate. The main fragments’ assignment is
indicated in the spectrum. The proposed structure is reported in the inset

with the observed sugar ring fragmentations (0,4A2 and 0,2A2). The loss of
C 12 H 24 O (184 mass units) is also indicated and was due to a
rearrangement typically occurring on primary 14:0 (3-OH) acyl chains
only when their 3-OH group is free, thus contributing to the establishment
of the location of the secondary acyl substitution
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The negative-ion MS2 spectrum of precursor ion at m/z
1522.6 (Fig. 3), identified as a mono-phosphorylated pentaacylated lipid A species, was chosen to settle the location of
the secondary acyl moieties. In detail, the MS2 spectrum
showed an intense peak at m/z 1278.6 matching with an ion
derived from the loss of one hydroxylated 14:0 moiety
(Fig. 3). In addition, the peak at m/z 1038.5, assignable to an
ion originating from the sugar ring fragmentation 0,2A2,
proved that the non-reducing glucosamine unit was decorated
by three acyl chains, that is plausibly two primary 14:0 (3-OH)
and one secondary 14:0 (2-OH). The absence of fragments
matching with the loss, from the precursor ion, of a whole unit
of a hydroxylated 14:0 fatty acid carrying a secondary hydroxylated 14:0 unit, suggested that the secondary acyl substitution
occurred on the N-linked primary acyl chain. Likewise, the
absence of a peak matching with an ion derived from the
sequential loss of one 14 (OH) and one 12 (OH), suggested
that the latter was in an acyloxyacyl moiety. Finally, and further supporting the structural assessment, the peaks at m/z
812.3 and m/z 794.2 were assigned to the sugar ring fragmentation 0,2A2 plus the loss of one hydroxylated 14:0, likely the
primary ester-bound acyl moiety, eliminated as either a free
fatty acid (m/z 794.2) and as a ketene derivative (m/z 812.3).
Since the data from MS2 analyses led to locate the secondary acyl substitution only on the primary amide-bound fatty
acids, an aliquot of lipid A was subjected to a treatment with
NH4OH [21]; this procedure by selectively removing the acyl
and acyloxyacyl esters, while leaving the acyl and
acyloxyacyl amides unaltered, is typically crucial in providing
a clear indication of the location of the lipid A acyl chains. The
MALDI-TOF MS spectrum, recorded in negative polarity, of

the NH4OH-treated lipid A is reported in Fig. 4. It clearly
showed three main peaks at m/z 1279.9, 1359.9 and 1375.9
matching with mono- (m/z 1279.9) and bis-phosphorylated
(m/z 1359.9 and 1375.9) tetra-acylated lipid A species carrying the sole primary N-linked hydroxylated 14:0 acyl chains in
turn substituted by the secondary fatty acids, which were unaffected by the NH4OH treatment. This definitively proved
that the secondary acyl substitution in the lipid A from
P. pulmonicola RL8228 exclusively occurs on the primary
amide-bound fatty acids.
In conclusion, to shed light on the actual presence of lipid
A species decorated by additional HexN(s) linked to the
diglucosamine backbone via the phosphate group(s), the precursor ion at m/z 1457.5 was analyzed by negative-ion MS2.
The spectrum (Fig. 5) showed an intense peak at m/z 1296.5
attributed to an ion derived from the loss of a HexN unit,
whereas peak at m/z 1213.5 was assigned to an ion generated
by the loss of one hydroxylated 14:0 moiety. The occurrence
of the peak at m/z 913.3, identified as an ion derived from the
sugar ring fragmentation 0,4A2, proved that the additional
HexN unit was on the phosphate decorating the nonreducing glucosamine unit, in turn acylated by two hydroxylated 14:0 residues. In parallel, peak at m/z 973.4 (0,2A2) confirmed the location of the additional HexN as well as the
location of the secondary acyl chain (12:0 (2-OH)) in the
acyloxyacyl amide moiety of the reducing glucosamine unit
(Fig. 5). Moreover, at low molecular masses an ion matching
with HexN-PO3 (m/z 240.12) has been also detected (Fig.
S-2). In conclusion, despite chemical analyses only showed
the presence of GlcN in the isolated lipid A fraction, in order
to unequivocally define the nature of the additional HexN

Fig. 3 Negative-ion MALDI MS2 spectrum of precursor ion at m/z
1522.6 of the lipid A isolated from. P. pulmonicola RL8228. This is a
representative ion peak of the cluster attributed to penta-acylated lipid A

species decorated by one phosphate. The main fragments’ assignment is
indicated in the spectrum. The proposed structure is given in the inset
with the observed sugar ring fragmentations (0,4A2 and 0,2A2)
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Fig. 4 Negative ion MALDI-TOF (reflectron mode) mass spectrum of the lipid A after NH4OH hydrolysis. *Indicates the structure sketched in the inset.
“P” indicates the phosphate group; “HexN” indicates differences of 161 amu (i.e. a hexosamine unit)

decorating some lipid A species of P. pulmonicola RL8228
LPS, an aliquot of lipid A underwent a dephosphorylation
treatment; this was followed by derivatization to alditol acetates of the unknown HexN properly separated from the lipid
A moiety, which was then investigated by means of GC-MS

(Fig. S-3). This analysis revealed the occurrence of
glucosaminitol acetate, thus finally demonstrating that the additional HexN unit decorating the disaccharide backbone of
some lipid A species from P. pulmonicola RL8228 was a
GlcN.

Fig. 5 Negative-ion MALDI MS2 spectrum of precursor ion at m/z
1457.5 of the lipid A isolated from P. pulmonicola RL8228. This is a
representative ion peak of the cluster ascribed to tetra-acylated lipid A
species decorated by one phosphate and one hexosamine via
phosphodiester bridge. The main fragments’ assignment is indicated in

the spectrum. The proposed structure is reported in the inset with some of
the observed sugar ring fragmentations (0,4A2 and 0,2A2). The α
configuration at the anomeric center of the GlcN unit was tentative.
“HexN” indicates differences of 161 amu (i.e. a hexosamine unit)
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Discussion
Chronic lung infection by Pandoraea species is an emerging
concern for the care and treatment of CF patients. Indeed, after
a first colonization, Pandoraea species are not only able to
chronically colonize the respiratory tract of CF individuals,
but they are also easily transmitted between patients causing
an aggravation of the lung disease and bacteremia [28]. In this
frame, P. pulmonicola strains have been identified as the most
virulent among the other Pandoraea species reported so far,
both in in vitro and in vivo models [5]. This has been associated to their capability to invade lung tissues and to their
resistance to a broad spectrum of antibiotics commonly used
for the treatment of bacterial infections in CF. However, the
contribution of P. pulmonicola to pathology progression in CF
patients is not fully understood. In large measure, this lack of
information is due to the still scant reports in clinical and
research literature outlining their colonization of CF lung
and their associated virulence factors.
To gain an insight into the potential virulence mechanisms
of P. pulmonicola, we focused the attention on the main constituent of its outer membrane, the LPS molecule. As a potent
elicitor of the host immune system, the LPS, and in particular its
lipid A moiety, surely has a role in the virulence of this bacterium. Here we characterized the lipid A structure isolated from
the smooth-type LPS of the chronic strain P. pulmonicola
RL8228. The lipid A turned out to be a complex mixture of
species differing by nature and number of the acyl chains, but
also for the phosphate content and the additional decoration on
one or both the phosphate groups with GlcN. Briefly, tri- to
penta-acylated lipid A species carrying one or two phosphates
have been identified, decorated by hydroxylated 14:0 as primary acyl chains, while various secondary fatty acids (i.e. 12:0 (2OH), 14:0 (2-OH), 14:0 and 12:0) were found (Fig. 6). In particular, the main lipid A species, detected at m/z 1376.4, was
matched with a bis-phosphorylated tetra-acylated form carrying
two primary hydroxylated 14:0 units on the non-reducing glucosamine, and one primary N-linked hydroxylated 14:0 in turn
substituted by the secondary 12:0 (2-OH) fatty acid on the
reducing glucosamine. Lipid A species decorated by an additional hydroxylated 14:0, yielding the penta-acylated forms
were also identified. Furthermore, as stated above, lipid A species decorated by one or two GlcN residues linked via phosphodiester bonds have been detected. A visual summary of all
the structural variations observed in such a complex lipid A
blend is reported in Fig. 6.
Interestingly, the structural elucidation of the sole lipid A
from P. pulmonicola RL8228 S-LPS already revealed several
structural features that could give, although preliminary, an
explanation to the exceptional virulence of this strain as well
as its capability to chronicize in CF lungs. Indeed, (i) the
capability to express different lipid A species simultaneously
with varying abundance, (ii) the low degree of acylation (less

Fig. 6 Summary of the variable structural features observed for
P. pulmonicola RL8228 lipid A. Some of the observed incompleteness
of the substitutions are reported as dotted-line bonds. The secondary acyl
moieties can also be non-hydroxylated and the possible occurring fatty
acids have been indicated as suggested also by chemical analyses data.
The α configuration at the anomeric center of the GlcN units was
tentative

than six acyl chains), (iii) the unusual fatty acid asymmetry
and variability at position 3 and 3’, (iv) the 2-hydroxylation of
both 14:0 and 12:0 in the acyloxyacyl positions at 2 and 2’, as
well as (v) the occurrence of the additional decoration by
GlcN of the phosphate groups, are surely of note for this lipid
A structure. Most of these characteristics are considered as a
trick adopted by bacteria to escape the host immune surveillance and thus enabling their persistence in the infected tissue.
Indeed, it is known that some lipid As with less than six acyl
chains are able to only poorly induce the TLR4 activation and
resulting responses, thus avoiding the anti-bacterial effects
derived from the induction of pro-inflammatory cytokines
production [9]. Moreover, the presence of positively charged
substituents, that is the GlcN, on the phosphate groups, “neutralizing” their negative charge, is known to strengthen bacterial resistance to host-derived cationic antibacterial peptides,
but also to reduce bacterial susceptibility to penetration by
commonly used cationic antibiotics [10–13]. Also, it has been
demonstrated, for other CF pathogens, that the 2hydroxyacylation of the lipid A is involved in abrogation of
the innate immunity inflammatory response, thus rendering
the bacterium less prone to be cleared from the lungs [29].
This is plausibly due to the fact that the presence of additional
hydroxylated acyl chains, in place of non-hydroxylated ones
as secondary substituents, may result in an increment of the H
bonding between neighboring LPS molecules in the bacterial
outer membrane, thereby incrementing the stabilization of the
membrane itself and likely increasing resistance to antibiotic/
antimicrobial peptides-induced bacterial killing.
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Notably, some structural features found for the
P. pulmonicola RL8228 lipid A resemble those observed for
another respiratory tract pathogens, i.e. Bordetella sp. Indeed,
a similar fatty acid composition and distribution with the respect to the glucosamine disaccharide backbone has been observed for some Bordetella species, in addition to the occurrence of the additional glucosamine substituting one or both
lipid A phosphate groups [30]. However, in contrast to
P. pulmonicola RL8228, in Bordetella sp. short-chain fatty
acids (10:0 (OH)) are commonly found, in addition to the
occurrence, in some strains, of 16:0 as a modification required
for persistent colonization of the mouse respiratory tract, [31]
and for protection from complement-mediated killing during
Bordetella respiratory infection [32].
How and at what extent the above structural features determined for P. pulmonicola RL8228 lipid A are involved in the
pathogenicity of such an emerging CF pathogen is currently
under investigation in the context of a detailed structure to
function relationship study.

Conclusions
This is the first report on the structure of the LPS lipid A
moiety isolated from Pandoraea species. Here we investigated the structure of the lipid A from the chronic strain
P. pulmonicola RL8228. This highly virulent CF pathogen
showed to express a complex blend of lipid A species which
differ in both the phosphate content, the nature and number of
the acyl chains. Furthermore, some lipid A species have been
found decorated by additional GlcN via phosphodiester
bridge. The combination of the structural features observed
in the lipid A are likely connected to the capability of this
strain to persist in the CF lungs avoiding detection by the host
immune system as well as its disruption by the most commonly used antibiotics. Similarly, we have previously characterized the O-chain structure of the LPS isolated from another
P. pulmonicola strain (LMG 18,108) and demonstrated that it
was made up of the trisaccharide repeating unit [→2-β-DQui3N-(1→4)-α-D-GalNAc-(1→3)-α-D-GlcNAc-1→]
where a five-membered ring aglycon residue has been found
covalently linked to the amine group of Qui3N [33]. As the Ochain is the antigenic portion of the LPS, conferring the
uniqueness indispensable for antibody recognition, the occurrence of this non-sugar appendage was hypothesized to have a
role in preventing the recognition of the bacterium by host
immune system. In this perspective, future studies are currently ongoing to define the full structure of the saccharide component of the LPS from P. pulmonicola RL8228 and the immunological properties of the whole molecule.
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